Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: A pilot study

European Journal of Medical Research

Volumn 19, Issue 1, 2014, Pages

  Matuschek, Christiane ^a   Lehnhardt, Marcus ^c   Gerber, Peter Arne ^a   Poremba, Christopher ^a,f   Hamilton, Jackson ^d   Lammering, Guido ^a   Orth, Klaus ^e   Budach, Wilfried ^a   Bojar, Hans ^a   Bölke, Edwin ^a   Peiper, Matthias ^a,b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Eye Hospital   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Klinik für Allgemein Visceral und Thoraxchirurgie   (Germany)

^f Pathologie München Nord ^*  (Germany)

Author keywords

CD44; Malignant fibrous histiocytoma; MFS; Myxofibrosarcoma; Soft tissue sarcoma; Survival; Tumor prognosis

Indexed keywords

CD44V6 ANTIGEN; HCD44 ANTIGEN; HCD44S ANTIGEN; HCD44V6 ANTIGEN; HCD44V8 ANTIGEN; HERMES ANTIGEN; RNA; UNCLASSIFIED DRUG; CD44 PROTEIN, HUMAN; ISOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MIDDLE AGED; PILOT STUDY; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; VERY ELDERLY; BIOSYNTHESIS; FIBROSARCOMA; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; FEMALE; FIBROSARCOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN ISOFORMS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84896768376     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-19-6     Document Type: Article

References (29)

1. Survival in primary soft tissue sarcoma of the extremities and trunk. Peiper M, Zurakowski D, Zornig C, Langenbecks Arch Chir 1997 382 203 208 9396000
2. Survival in patients with primary soft-tissue sarcomas treated within 6 years. Peiper M, Zurakowski D, Schwarz R, Weh HJ, Zornig C, J Cancer Res Clin Oncol 1998 124 199 206 10.1007/s004320050155 9619747
3. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer. Kawano T, Nakamura Y, Yanoma S, Kubota A, Furukawa M, Miyagi Y, Tsukuda M, Auris Nasus Larynx 2004 31 35 41 10.1016/j.anl.2003.09.005 15041052
4. The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer. Nihei Z, Ichikawa W, Kojima K, Togo S, Miyanaga T, Hirayama R, Mishima Y, Surg Today 1996 26 760 761 10.1007/BF00312104 8883258
5. CD44H plays an important role in peritoneal dissemination of scirrhous gastric cancer cells. Nishimura S, Chung YS, Yashiro M, Inoue T, Sowa M, Jpn J Cancer Res 1996 26 1265 1244
6. Different CD44 splicing patterns define prognostic subgroups in multiple myeloma. Stauder R, van Driel M, Schwarzler C, Thaler J, Lokhorst HM, Kreuser ED, Bloem AC, Günthert U, Eisterer W, Blood 1996 88 3101 3108 8874209
7. CD44 cell adhesion molecules. Goodison S, Urquidi V, Tarin D, Mol Pathol 1999 52 189 196 10.1136/mp.52.4.189 10694938
8. Progressive loss of CD44 gene expression in invasive bladder cancer. Sugino T, Gorham H, Yoshida K, Bolodeoku J, Nargund V, Cranston D, Goodison S, Tarin D, Am J Pathol 1996 149 873 882 8780391
9. CD44s expression is associated with improved survival in soft tissue sarcoma. Peiper M, Sato T, Zurakowski D, Eisenberger CF, Heinecke A, Hosch SB, Knoefel WT, Anticancer Res 2004 24 1053 1056 15154622
10. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Khan SA, Cook AC, Kappil M, Günthert U, Chambers AF, Tuck AB, Denhardt DT, Clin Exp Metastasis 2005 22 663 673 10.1007/s10585-006-9007-0 16691370
11. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Ponta H, Herrlich P, Cell 1991 65 13 24 10.1016/0092-8674(91)90403-L 1707342
12. Hyaluronan production increases the malignant properties of mesothelioma cells. Li Y, Heldin P, Br J Cancer 2001 85 600 607 10.1054/bjoc.2001.1922 11506502
13. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Nguyen VN, Mirejovsky T, Melinova L, Mandys V, Neoplasma 2000 47 400 408 11263866
14. The gene for human lymphocyte homing receptor is located on chromosome 11. Forsberg UH, Ala-Kapee MM, Jalkanen S, Andersson LC, Schroder J, Eur J Immunol 1989 19 409 412 10.1002/eji.1830190228 2467821
15. Expression of CD44 by rhabdomyosarcoma: a new prognostic marker? Humphrey G, Hazel DL, MacLennan K, Lewis I, Br J Cancer 1999 80 918 921 10.1038/sj.bjc.6690442 10360676
16. Nonparametric estimation from incomplete observations. Kaplan EL, Meier P, J Am Stat Assoc 1958 58 457 481
17. Regression models and life-tables (with discussion). Cox DR, J Royal Stat Soc 1972 34 187 220 Series B
18. Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s. Terpe HJ, Christiansen H, Gonzalez M, Berthold F, Lampert F, Eur J Cancer 1995 31A 549 552 7576965
19. Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma. Gotoda T, Matsumura Y, Kondo H, Ono H, Kanamoto A, Kato H, Watanabe H, Tachimori Y, Nakanishi Y, Kakizoe T, Gut 2000 46 14 19 10.1136/gut.46.1.14 10601048
20. Expression of CD44 variants in osteosarcoma. Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, Inoue H, J Cancer Res Clin Oncol 1999 125 646 652 10.1007/s004320050329 10541973
21. Prognostic significance of CD44 and nm23 expression in patients with stage II and stage IIIA gastric carcinoma. Yoo CH, Noh SH, Kim H, Lee HY, Min JS, J Surg Oncol 1999 71 22 28 10.1002/(SICI)1096-9098(199905)71:1<22::AID- JSO5>3.0.CO;2-I 10362087
22. CD44 expression in soft tissue sarcomas. Kahara N, Ozaki T, Doi T, Nishida K, Kawai A, Shibahara M, Inoue H, Virchows Arch 2000 436 574 578 10.1007/s004289900159 10917171
23. The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas. Maula S, Huuhtanen RL, Blomqvist CP, Wiklund TA, Laurila P, Ristamaki R, Br J Cancer 2001 84 244 252 10.1054/bjoc.2000.1590 11161384
24. Novel animal model of lymph node metastasis by intrauterine inoculation of the actively metastatic subline PL3 separated from rat Walker 256 tumor cells. Hashii K, Tohya K, Kimura M, Tateyama I, Mori T, Kadota E, Hashimoto S, Tomura T, Invasion Metastasis 1997 17 149 157 9702941
25. Expression profiling using tissue microarray in 211malignant fibrous histiocytomas confirms the prognostic value of Ki-67. Nilbert M, Alveg R, Thor A, Rydholm A, Weide J, Bjerkehagen P, Domanski B, Henryk A, Kerman P, Bendahl P, Persson A, Engellau J, Virchows Arch 2004 445 224 230 10.1007/s00428-004-1065-6 15309631
26. New CD44 splice variant associated with human breast cancers. Iida N, Bourguignon LY, J Cellular Physiol 1995 112 127 133
27. Expression of CD44v6 and PCNA in squamous cell carcinomas. Niu Y, Liu F, Zhou Z, Wang H, Chinese Med J 2002 115 1564 1568
28. Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity. Yang K, Tang Y, Habermehl GK, Iczkowski KA, BMC Cancer 2010 10 16 10.1186/1471-2407-10-16 20074368
29. Miettinen M, Diagnostic soft tissue pathology Philadelphia: Churchill Livingstone 1 2003